History

Illumina founded by David Walt, Ph.D., of Tufts University (inventor of BeadArray technology), Larry Bock of the CW Group, John Stuelpnagel, D.V.M., Anthony Czarnik, Ph.D., and Mark Chee, Ph.D.

Illumina begins with a staff of seven, secures a 10,000 sq. ft. facility in San Diego, CA, and begins developing core technology and intellectual property portfolio with initial funding of $8.6 million.

Jay Flatley joins Illumina as President and Chief Executive Officer.

Illumina’s IPO raises over $100 million.

Illumina offers genotyping services using its production-scale systems and GoldenGate Genotyping Technology. The first services contract with GlaxoSmithKline comes through in May 2001.

Illumina’s turnkey, fully-integrated production SNP genotyping system was introduced as a commercial solution for leading genotyping facilities around the world. More than 60% of the data for the International HapMap project Phase I was generated using this platform and the GoldenGate Assay.

Illumina launches a second genetic analysis application, gene expression profiling. Illumina’s gene expression arrays feature the world’s first multi-sample chip formats and the industry’s only 100% array QC.

Illumina technology becomes available to core labs and researchers around the globe with the launch of the BeadStation system, a benchtop solution that runs both DNA and RNA analysis applications. The Illumina BeadStation brings scalability and flexibility to genetic analysis researchers through its modular format and integrated options.

Illumina launches the DASL Assay, a powerful new approach for generating gene expression profiles from partially degraded RNA samples such as those found in formalin-fixed, paraffin-embedded samples (a common method of preserving samples from biopsies). An estimated 400 million FFPE samples exist in the U.S. for cancer alone.

Illumina acquires CyVera Corporation, the developer of VeraCode Technology, a complementary, low-multiplex technology that is ideal for target validation and molecular test development.

Illumina launches the world’s first multi-sample, whole-genome expression microarrays. The Human-6 and HumanRef-8 BeadChips deliver industry-leading quality and pricing.

Illumina launches the Infinium Assay, a revolutionary genotyping assay that provides intelligent SNP selection and unlimited access to the genome. The first Infinium product, the Human-1 Genotyping BeadChip, includes over 100,000 markers on a single BeadChip.

Illumina introduces the world’s first whole-genome expression arrays for mouse, an important model organism.

Illumina announces the availability of the HumanHap300 Genotyping BeadChip, which leverages tag SNP content to deliver over 300,000 markers on a single microarray.

Illumina expands its standard panel offering for GoldenGate genotyping with three new panels for the MHC region, cancer, and sample quality assessment.

Illumina announces the next BeadChip in its Infinium whole-genome genotyping offering, the HumanHap550 BeadChip, with over 550,000 markers on a single microarray.

Illumina announces custom content for Infinium genotyping with the HumanHap550+ and iSelect BeadChip.

Illumina announces the third BeadChip in its Infinium whole-genome genotyping offering, the HumanHap650Y BeadChip, with over 650,000 markers on a single microarray and enriched content for African populations.

Illumina announces a program certifying service labs around the world to provide genotyping and gene expression services using its BeadArray technology.

Illumina introduces the world’s first whole-genome expression arrays for rat, an important model organism.

Illumina announces the acquisition of Solexa, the developer of a genomic-scale sequencing technology. Combined, illumina now offers the ultimate tool set for genetic analysis.

Illumina launched the GoldenGate Methylation Cancer Panel, capable of surveying up to 1,536 methylation sites across 96 samples simultaneously,

Combining an unprecedented level of content for both whole-genome and copy number variation analysis, the Human1M and Human450S BeadChips include additional unique, high-value genomic regions of interest - all on a single microarray chip.

Illumina posted its first profitable 12-month period in five years, making its way to #1 on Forbes' fastest growing high-tech list.

Developed in collaboration with deCODE genetics, the HumanCNV370-Duo, is the world’s first microarray designed to specifically target novel regions of the genome that show copy number variation.

Utilizing uniquely inscribed digital microbeads, the VeraCode technology provides high-quality data, broad multiplexing capability, and assay flexibility. Researchers can assay tens to hundreds of analytes in a single sample at one time.

Using the custom DNA methylation panels investigators now have the option to select their favorite genes or gene regions to cost-effectively survey up to 1,536 methylation sites of choice across 96 samples simultaneously.

IlluminaConnect is a bioinformatics software partnership program established to advance data integration and analysis. This program offers Illumina customers seamless access to third-party bioinformatics providers of advanced data analysis applications for processing Illumina array data.

iControlDB is the first industry-hosted genotyping control repository available for researchers conducting case-control whole-genome association studies.

New Digital Gene Expression (DGE) applications including small RNA and Gene Expresion profiling use Illumina’s Genome Analyzer to generate genome-wide sequencing-based expression profiles of messenger and small RNA.

The HumanHap550-Duo BeadChip is the Company’s fourth multi-sample DNA Analysis solution for genome-wide association studies. The HumanHap550-Duo BeadChip provides the same content as the HumanHap550 BeadChip but in a dual-sample format, resulting in significantly greater throughput and lower cost per sample.

The HumanLinkage-12 BeadChip is Illumina’s fifth multi-sample Infinium BeadChip and the Company’s first standard panel to take advantage of a twelve-sample format for linkage analysis.

Priced at $95 per sample, the MicroRNA Assay for Gene Expression profiling is the only tool available to allow rapid and reproducible miRNA expression profiling at a price less than half that of other commercially available methods.

New DNA Methylation BeadChip assays 27,000 CpG sites per sample, covering more than 14,000 well-annotated genes with single CpG resolution.

Illumina reorganized its operating structure to further leverage the synergies between its sequencing and genotyping businesses.

The Infinium HD Human1M-Duo (two samples/chip) and the Human610-Quad (four samples/chip) feature up to 2.3 million single nucleotide polymorphisms (SNPs) per BeadChip, doubling sample throughput and reducing DNA input requirements by as much as 70 percent.

The Infinium BovineSNP50 BeadChip is a 12-sample genotyping product featuring 54,000 SNPs for detecting genetic variation in any breed of cattle.

Illumina scientists sequenced the genome of an anonymous African male (Yoruba from Ibadan, Nigeria), using the Genome Analyzer. This achievement establishes the direct utility of Illumina’s sequencing technology for accurately sequencing large and complex genomes